DOCSLIB.ORG

VIII. Appendix 'G =: 0

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
VIII. Appendix 'G =: 0 '0> VIII. Appendix 'g =: 0.. Structures, systematic, trivial, generic and trade names of protein anabolic steroids ~. Structure Systematic name" Trivial and/or generic name Trade name Manufacturer L.T!'''..tosterQ!.le-deril1ed l!.rote~anabolic steroids 17 fi-Hydroxyandrost- Testosterone Geno-cristaux Gremy H 4-en-3-one Malestrone Kirk, N.Y. cOVo Orquisteron/Frosst (Columbia) Primotest Schering A.G. o 0 Oreton Schering -acetate Aceto-Sterandryl Roussel Aceto-Testoviron Schering A.G. Perandrone A ClBA -propionate Oreton Schering Perandren Ciba-Geigy Sterandryl Roussel Testoviron Schering Anertan Boehringer (M) Enarmon Takeda (Japan) -(3-p-hexyloxiphenyl)- Androdurin Leo, propionate (Helsingborg) -heptanoate (enanthate) Delatestryl Squibb Androtardyl Schering-Sepps Testoenant Geymonod -cycJopentyl propionate Depot testosterone Upjohn cypionate 4-Ch1oro-17 fi-hydroxy- Chlorotestosterone Steranabol Farmitalia androst-4-en-3-one -acetate Macrobin Teikoku ~Ol! Turinabol Jenapharm Turinabol inj. Jenapharm 0\ o 0 IV -capronate Macrobin-depot Teikoku -...J Cl 0\ Appendix (continued) tv 00 Structure Systematic namea Trivial and/or generic name Trade name Manufacturer 17 P-Hydroxy-17-methyl- Methyltestosterone Metandren Ciba androst-4-en-3-one Anertan Boehringer (M) Oreton Schering *OH Android Brown o ~ CH 3 9cx-Fluoro-llp,17P-dihydroxy- Fluoxymesterone Halotestin Upjohn 17-methylandrost-4-en-3-one Ultandren Ciba Androfluorene Midy 0£UOH Fluotestin Roter o ~ Orateston Hoechst CH 3 4,17 P-Dihydroxy-17-methyl- Oxymesterone, Oranabol Farmitalia androst -4-en -3-one 4-Hydroxymethyltestosterone Kabi Lipfa Q5DOIl May & Baker o ~ Sanaboral Ikapharm Theranabol Theraplix OH IIIX,17 P-Dihydroxy-17-methyl- lllX-Hydroxy- etsDoH androst-4-en-3-one methyltestosterone o ~ 17p-Hydroxy-17-methyl- 11-0xomethyltestosterone androst-4-ene-3,11-dione ct)BoH '0>- '0 (1) ::l o ~ 0- >;" Appendix (continued) Structure Systematic name" Trivial and/or generic name Trade name Manufacturer '0;..- '0 (1l CH 3 4-Chloro-17 fJ-hydroxy-17 -methyl- Chloromethyitestosterone Turinabol tab!. Jenapharm ::l q950H androst-4-en- 3-one ~ o ,-::; Cl CH 3 liX,7iX-Bis(acetylthio)- Thiomesterone Emdabol Merck A.G. ". OH 17 fJ-hydroxy-17-methyl- CH~ androst-4-en-3-one "'SCOCH o ~ 3 17 j3-Hydroxy-17-methyl- Methandrostenolone Dianabol Ciba androsta-l,4-dien-3-one Methandienone Abirol Takeda I-Dehydromethyltestosterone Geabol Gea mBoH Nabolin Eisai Nerobil Richter o ,-::; Vanabol Vitrum -cyclopentenyl ether Anabolicus Vister (gen.) Quinbolon 4-Chloro-17 j3-hydroxy- Chloro-l-dehydromethyl- Oral-Turinabol Jenapharm 17 -methylandrosta-l,4-dien- testosterone ~OH 3-one o ,-::; Cl CH 3 17 j3-Hydroxy-7iX, 17iX-dimethyl- Bolasterone, Myagen Upjohn ", OH androst-4-en-3-one Dimethyltestosterone Callusterone Methosarb Upjohn 0'1 oo2? N\0 0\ w Appendic (continued) 0 Structure Systematic name" Trivial and/or generic name Trade name Manufacturer II. J9-N ortestosterone-derived protein anabolic steroids 17[3-Hydroxyestr-4- 19-N ortestosterone Nerobolil Medimpex H en-3-one Nandrolone Nortestonate Upjohn oSDo -n-capronate Methybol-depot Mepha -propionate Norybol Serono o ~ Anabolicus-Serono Ausonia -phenyl propionate Activin Aristegui Durabol Pharmacia Durabolin Organon Nerobolil Richter Neutrosteron Organon -furylpropionate Demolon Mochida -hexahydrobenzoate Nor-Durandon Ferring -hexyloxyphenylpropionate Anadur Leo-Lundbeck -Iaurate Laurabolin Organon (Vet.) -undecylate Dynabolon Theramex -decanoate Abolon Benzon Deca-Durabol Pharmacia Deca-Durabolin Organon Eubolin Futerapica Nordecon IBSA Retabolil Richter -hemisuccinate Menidrabol Menarini -cyclohexylpropionate Fherbolico Fher Sanabolicum Sanabo -cyclopentylpropionate Sterocrinolo Orma Depo-N ortestonate Upjohn Pluropon Boehringer '0;I> '0 -4-methylbicyclo[2.2.2Joct- Syntex (1) 2-ene-I-carboxylate 0-::s ;;<. Appendix (continued) g'0>- Structure Systematic name" Trivial and/or generic name Trade name Manufacturer 0. :;;;" 4,17 fJ-Dihydroxyestr- Oxabolone Steranabol-depot Farmitalia 4-en-3-one 4-hydroxy-19-nortestosterone qSX50H -cycJopentylpropionate o .d OR 4-Chloro-17 fJ-hydroxyestr- Chloro-19-nortestosterone qSX50H 4-en-3-one -acetate Steranabol FarmitaJia o .d CI 17 fJ-Hydroxy-17-methyl- Methyl-19-nortestosterone Methalutin Syntex ~OH estr-4-en-3-one Orgasteron Organon o .d 17 fJ-Hydroxy-19-nor- N orethandrolone Nilevar Searle pregn-4-en-3-one Ethylnortestosterone Nor-Neutrormone ICI Pronabol Isis bH -propionate Solevar Byla oo13 .d 17fJ-Hydroxy-19-nor- Ethyldienolone ~bH pregna-4,9-dien-3-one a- o .d w 0'1 W Appendix (continued) N Structure Systematic name" Trivial and/or generic name Trade name Manufacturer HSC2 (dl)-17 {3-Hydroxy-13{3,17rx­ Norbolethone Genabol Wyeth C2Hs dieth ylgon A-en -3-one . OH (dl)-13-EthYI-17- ) ( hydroxy-18,19-dinor- 17rx-pregn-4-en-3-one o I I I. Androstane-derived protein anabolic steroids 3{3-Hydroxy-5rx-androstan- Epiandrosterone no* 17-one Isoandrosterone 17 {3-Hydroxy-5rx­ Androstanolone Anaboleen B.A.G. androstan -3-one Stanolone Uni Chemie Dihydrotestosterone Anabolex Lloyd-Hamol o&on Samil Androlone Orma Proteina Gremy Protona Gremy Apeton Fujisawa -valerian ate Apeton depot Fujisawa 3rx-Hydroxy-5rx­ Androsterone androstan-17 -one >­ 1I0cJ5rl g"0 0- ~. Appendix (continued) Structure Systematic namea Trivial and/or generic name Trade name Manufacturer > 17 P-Hydroxy-2ct-methyl- Drostanolone Drolban Lilly ] Q.. 5ct-androstan-3-one 2ct-Methylandrostanolone Masterone Recovdati ~. H3C ... Sarva *OH Syntex o : 2ct-Methyldihydrotestosterone Metorman Latino -propionate Mastizol Shionogi 17 P-Hydroxy-lct-methyl- Mesterolone Mestoran Schering 5ct-androstan-3-one (Denmark) asuOH Proviron Schering A.G. o : 5ct-Androstane-3p,17 P-diol- Androstanediol- Ectovis Vister o*OH 3-n-octyl-enol-ether 3-n-octyl-enol ether Ectovister Drovyssa \ . n-CSH7 CH3 17 p-Hydroxy-17 -methyl- Mestanolone Ermalon Roussel 5il-androstan-3-one Methylandrostanolone Androstalone Roussel *OH -enanthoyl-acetate N otandron-depot Boehringer (M) o .: CH3 17 P-Hydroxy-17-methyl- Oxymetholone Adroyd Parke-Davis ... OH 2-(hydroxy-methylene)- Sankyo 5ct-androstan-3-one Anadrol Shionogi Syntex HOCH~xX(5 Anadroyd Parke-Davis Anapolon ICI Anasterone Syntex Anasterona Latino Nastenon Cassenne w~ Protanabol Recordati Synasterobe Sarva 0\ w Appendix (continued) .j>. Structure Systematic namea Trivial and/or generic name Trade name Manufacturer IV Heterocyclic protein anabolic steroids 17-Methyl-51X-androstano- Stanozolol Winstrol Yamanouchi [3,2-c]-pyrazol-17 f3-ol Winthrop Zambon HC,20H Stromba Winthrop HN' \W : Tevabolin Teva 17-Methyl-51X-androstano- Androisoxazole Androxan Leo-Lundbeck [3,2-c]-isoxazol-17 f3-ol Neo-Ponden Serono Neo-Pondus Ausonia HC,20H 0' \N'" : CH 3 2',17-Dimethylandrost-5(10)- eno[3,2-dJ-thiazol-17f3-ol ?~url C~ :1 3-Azi-17-methyl-51X- Methyldiazirinol H androstan-17f3-ol NaOII " N : 17 f3-Hydroxy-21X, 17-dimethyl- Dimethazine Roxilon Richter 51X-androstan-3,3' -azine Dostalon Richter ( CH, '0:> j '0 (1) ~:nSXyH2 ::s0- ;;<" :» Appendix (continued) "0 "0 0 i:I Structure Systematic name' Trivial and/or generic name Trade name Manufacturer 0- :;;;. 17 f3-Hydroxy-17 -methyl- Oxandrolone Anavar Searle mEoH 2-oxa -SO(-androstan -3-one o : v. Miscellaneous structure protein anabolic steroids 17f3-Hydroxy-l-methyl- Methenolone Nibol Squibb SO(-androst-l-en-3-one Primobolan Schering A. G. H Primobolan-Acetate Schering A.G. JpDO -acetate -enanthate Primo bolan-Depot Schering A.G. CH3 17-Methyl-3-methylene-Sa:- androst-l-en-17f3-01 ~ca9=yH CH3 17-Methyl-androst-S- Methylandrostenediol Crestabolic Nutrition ene-3f3,17f3-diol Control Products H Methandriol Diandrin Astra HorO Megabion Teikoku Metilandrostendiol Schering A. G. Neosteron Organon Pharmacia Neutrormone lSI Notandren Boehringer (M) Protandren Ciba 0\ <.;.> Stenediol Organon Vl 0\~ Appendix (continucd) Structure Systematic namea Trivial and/or generic name Trade name Manufacturer -3-propionate Metilbisexovis Vister Methilbisexovister Drovyssa Metildiolo Orma -dipropionate Anabolin Rafa Metandiol Roussel -dienanthoylacetate N otandren-depot Boehringer (M) 3 p-H ydroxyandrost- Dehydroepiandrosterone Psicosterone ICI 5-en-17 -one Dehydroisoandrosterone Diandrone Organon lIoaSrl -acetate 17 -Chetovis Vister C2HS 19-N orpregn-4-en-17 p-ol Ethylestrenol Duraboral Organon Maxibolin Organon Orabolin Organon CJ500H Orgaboral Organon Durabolin-O Organon Orgabolin Organon 17IX-Oxo-D-homo-androsta- L1' -testololactone Teslac Squibb ~laOJO 1,4-diene-3,17-dione 1,2,3,4,4a,4b,7,9,lO,10a- ) OOJ~ ( decahydro-2-hydroxy-2, 4b-dimethyl-7-oxo-l­ phenanthrene propionic acid a Chemical Abstracts Systematic Name, Collective Subject Indices, Chemical Abstract. e. Prepared by ARNOLD, A., POTTS,G.O., and BEYLER,A.L. fQ.. ~. Author Index Page numbers in italics refer to bibliography Aakvaag,A., see Stromme, Adda,M. 581,599 Al brigh t, F., Parsons, W., S. B. 521,534 Addis, T., Lew, W. 121, 143 Bloomberg, E. 50,56,62,68 Abarbanei,A.R., see Rubinstein, Adler, P., see Poser, G. 547,618 Albright, F., Reifenstein, E. C. H.S. 73,152 Aebi, U., see Vassella, F. 561, 56,68 Abe,O., Herranen,A., 623 Albright, F., Smith,P. H., Fraser, Dorfman,R.L 197, 198,207 Aepli,R. 567,596,599 R. 167,177 Abe,O., see Rooks,W.H. Aegerter, E. A., see Shay, H. Albright, F., see Klinefelter, 197,209 201,202,209 H. F., Jr. 456,477 Abe,O., see Takatani,O. 193, Agafonowa,G.A., see Sinitzin, Albright, F., see Reifenstein, 210 P.D. 557,621 E.C.,Jr. 8,43,388,405425, Abeliuk,J., see Vargas,L. 78, Agapova, E. N., Tkachenko, 426, 427, 430, 434, 436, 438 108, 129, 132,153 A. M., Krutovskaya, O. V. Aleksandriva, L. M., see Tirkina, Abraham;R., Staudinger,Hj. 550,599 T. N. 571, 622 295,298,351 Agerty,H.A., see Seitchik,J. N. Alessi, E., see Bonelli, M. Abrahamson,M., see 449,481 175,178 Muldowney,F.P. 435,438 Ahlendorf, W., Kob,D. 581, Alexanian,R. 488,494 Abramowicz,M., see 599 Alexanian,R., see Adamson, Bettmann,H.K. 425,436, Ahn,C.S., see Rosenberg, LN. J. W. 488,494 452,473 467,480 Alfert, M., see Bern. H. A. Abritta,J. 465,472 Ahren,K., Arvil\,A., Hjalmar­ 118, 144 Aceto,M.D., see Watzman,N. son,A. 98,143 Alfin-Slater,R.
Load more

Recommended publications
  • CHAPTER 29 ORGANIC CHEMICALS VI 29-1 Notes 1
    )&f1y3X CHAPTER 29 ORGANIC CHEMICALS VI 29-1 Notes 1. Except where the context otherwise requires, the headings of this chapter apply only to: (a) Separate chemically defined organic compounds, whether or not containing impurities; (b) Mixtures of two or more isomers of the same organic compound (whether or not containing impurities), except mixtures of acyclic hydrocarbon isomers (other than stereoisomers), whether or not saturated (chapter 27); (c) The products of headings 2936 to 2939 or the sugar ethers and sugar esters, and their salts, of heading 2940, or the products of heading 2941, whether or not chemically defined; (d) Products mentioned in (a), (b) or (c) above dissolved in water; (e) Products mentioned in (a), (b) or (c) above dissolved in other solvents provided that the solution constitutes a normal and necessary method of putting up these products adopted solely for reasons of safety or for transport and that the solvent does not render the product particularly suitable for specific use rather than for general use; (f) The products mentioned in (a), (b), (c), (d) or (e) above with an added stabilizer (including an anticaking agent) necessary for their preservation or transport; (g) The products mentioned in (a), (b), (c), (d), (e) or (f) above with an added antidusting agent or a coloring or odoriferous substance added to facilitate their identification or for safety reasons, provided that the additions do not render the product particularly suitable for specific use rather than for general use; (h) The following products, diluted to standard strengths, for the production of azo dyes: diazonium salts, couplers used for these salts and diazotizable amines and their salts.
    [Show full text]
  • Stable Isotope-Labeled Productsfor Metabolic Research
    RESEARCH PRODUCTS Cambridge Isotope Laboratories, Inc. isotope.com Stable Isotope-Labeled Products For Metabolic Research Cambridge Isotope Laboratories, Inc. North America: 1.800.322.1174 [email protected] | International: +1.978.749.8000 [email protected] | fax: 1.978.749.2768 | isotope.com Cambridge Isotope Laboratories, Inc. | Stable Isotope-Labeled Products for Metabolic Research Stable Isotopes in Metabolomics and Metabolism Gary J. Patti Department of Chemistry, Washington University, St. Louis, Missouri 63130 United States Recent advances in mass spectrometry (MS) and nuclear comparing two sample groups, for example, an elevated magnetic resonance (NMR) technologies have greatly metabolite level may indicate increased or decreased enhanced metabolite analysis. Hundreds to thousands pathway flux. This is because metabolites can accumulate of metabolites can now be measured simultaneously with not only due to increased production, but also due to unprecedented accuracy from exceedingly small amounts decreased consumption. Yet, the difference between of biological material. These technical developments have increased production and decreased consumption may yield given rise to the field of metabolomics, which generally entirely different experimental interpretations. In a biomedical aims to assess metabolic regulation as a function of health context, for instance, increased production of a metabolite and disease. During the last decade, it has become relatively may suggest pharmacological inhibition of the pathway as a routine to perform metabolomic analysis on most biological therapeutic strategy. Thus, to understand pathway regulation samples. Interpretation of the acquired data, however, and metabolic mechanisms of disease, the application of remains a considerable challenge. Stable isotopes are isotopic tracers is required. providing experimental strategies that overcome some of these barriers.
    [Show full text]
  • Catalog Stable Isotope-Labeled Products for Metabolic Research
    Cambridge Isotope Laboratories, Inc. isotope.com Stable Isotope-Labeled Products For Metabolic Research Euriso-Top, Parc des Algorithmes, route de l'orme, 91190 Saint Aubin | France tel: +33 1 69 41 97 98 fax: +33 1 69 41 93 52 +49 (0) 681 99 63 338 (Germany) www.eurisotop.com Cambridge Isotope Laboratories, Inc. | Stable Isotope-Labeled Products for Metabolic Research Stable Isotopes in Metabolomics and Metabolism Gary J. Patti Department of Chemistry, Washington University, St. Louis, Missouri 63130 United States Recent advances in mass spectrometry (MS) and nuclear comparing two sample groups, for example, an elevated magnetic resonance (NMR) technologies have greatly metabolite level may indicate increased or decreased enhanced metabolite analysis. Hundreds to thousands pathway flux. This is because metabolites can accumulate of metabolites can now be measured simultaneously with not only due to increased production, but also due to unprecedented accuracy from exceedingly small amounts decreased consumption. Yet, the difference between of biological material. These technical developments have increased production and decreased consumption may yield given rise to the field of metabolomics, which generally entirely different experimental interpretations. In a biomedical aims to assess metabolic regulation as a function of health context, for instance, increased production of a metabolite and disease. During the last decade, it has become relatively may suggest pharmacological inhibition of the pathway as a routine to perform metabolomic analysis on most biological therapeutic strategy. Thus, to understand pathway regulation samples. Interpretation of the acquired data, however, and metabolic mechanisms of disease, the application of remains a considerable challenge. Stable isotopes are isotopic tracers is required.
    [Show full text]
  • Ricini Oleum
    PHARMACOGNOSY II PHAR306 6th Semester 5th Lecture Prof. Dr. Müberra Koşar Ass. Prof. Dr. Aybike Yektaoğlu Eastern Mediterranean University Faculty of Pharmacy Department of Pharmacognosy PHARMACEUTICAL FIXED OILS AND ANIMAL FATS FIXED OILS & ANIMAL FATS Amygdalae oleum • “Almond oil” • obtained by crushing of the seeds of two varieties Prunus dulcis var. dulcis or P. dulcis var. amara (Rosaceae) in the cold • Almond oil is obtained in the Mediterranean countries (Italy, France, Spain and North Africa) where its culture is obtained • The only difference between the two varieties is the cyanogenic glycoside content of the var. amara FIXED OILS&ANIMAL FATS Amygdalae oleum • seeds carries 40-55% fixed oil • the refined oil mainly contains oleic acid (62-86%), linoleic (20- 30%), palmitic (4-9%) • Amydalae oleum raffinatum (Almond oil, refined) (Eur.Pu.) • Amydalae oleum virginale (Almond oil, virgin) (Eur.Ph.) • major used in cosmetology and dermatology • used as a carrier in oily injectable preparations FIXED OILS&ANIMAL FATS Arachidis oleum • “Arachis oil, Peanut oil” – “Peanut butter” • Arachis hypogaea (Fabaceae) • cultivated in South America, China, India, Australia, and West Africa • due to various genotypes they vary in fatty acid content • the seeds are cold-pressed • they have similar properties as olive oil • most suitable oil for added for embedding purposes into other oils (e.g. olive oil) FIXED OILS&ANIMAL FATS Arachidis oleum - content • seeds carries 40-50% fixed oil • 50-65% oleic acid • 18-30% linoleic acid • 8-10% palmitic
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Medicines Regulations 1984 (SR 1984/143)
    Reprint as at 1 July 2014 Medicines Regulations 1984 (SR 1984/143) David Beattie, Governor-General Order in Council At the Government House at Wellington this 5th day of June 1984 Present: His Excellency the Governor-General in Council Pursuant to section 105 of the Medicines Act 1981, and, in the case of Part 3 of the regulations, to section 62 of that Act, His Excellency the Governor-General, acting on the advice of the Minister of Health tendered after consultation with the organisations and bodies that ap- peared to the Minister to be representatives of persons likely to be substantially affected, and by and with the advice and consent of the Executive Council, hereby makes the following regulations. Contents Page 1 Title and commencement 5 Note Changes authorised by subpart 2 of Part 2 of the Legislation Act 2012 have been made in this official reprint. Note 4 at the end of this reprint provides a list of the amendments incorporated. These regulations are administered by the Ministry of Health. 1 Reprinted as at Medicines Regulations 1984 1 July 2014 2 Interpretation 5 Part 1 Classification of medicines 3 Classification of medicines 11 Part 2 Standards 4 Standards for medicines, related products, medical 11 devices, cosmetics, and surgical dressings 5 Pharmacist may dilute medicine in particular case 12 6 Colouring substances [Revoked] 12 Part 3 Advertisements 7 Advertisements not to claim official approval 13 8 Advertisements for medicines 13 9 Advertisements for related products 15 10 Advertisements for medical devices 15 11 Advertisements
    [Show full text]
  • Anabolic-Androgenic Steroids in Horses: Natural Presence and Underlying Biomechanisms
    ANABOLIC-ANDROGENIC STEROIDS IN HORSES: NATURAL PRESENCE AND UNDERLYING BIOMECHANISMS Anneleen Decloedt Dissertation submitted in the fulfilment of the requirements for the degree of Doctor of philosophy (PhD) in Veterinary Sciences, Faculty of Veterinary Medicine, Ghent University PROMOTER Prof. dr. ir. Lynn Vanhaecke Ghent University, Faculty of Veterinary Medicine Department of Veterinary Public Health and Food Safety Laboratory of Chemical Analysis MEMBERS OF THE READING COMMITTEE Prof. dr. James Scarth HFL Sport Science, Cambridgeshire, United-Kingdom Prof. dr. Peter Van Eenoo Ghent University, DoCoLab, Zwijnaarde, Belgium Prof. dr. Ann Van Soom Ghent University, Faculty of Veterinary Medicine, Merelbeke, Belgium MEMBERS OF THE EXAMINATION COMMITTEE Dr. Ludovic Bailly-Chouriberry Laboratoires des Courses Hippiques, Verrières-le-Buisson, France Dr. Leen Van Ginkel Wageningen University, RIKILT, Wageningen, The Netherlands Prof. dr. Myriam Hesta Ghent University, Faculty of Veterinary Medicine, Merelbeke, Belgium This work was funded by the Fédération Nationale des Courses Françaises (via the Laboratoire des Courses Hippiques) and executed at the Laboratory of Chemical Analysis (Faculty of Veterinary Medicine, Ghent University, Merelbeke). The author and the promoter give the authorisation to consult and to copy parts of this work for personal use only. Every other use is subject to the copyright laws. Permission to reproduce any material contained in this work should be obtained from the author. “The universe is full of magic, Just patiently waiting for our wits to grow sharper” TABLE OF CONTENTS TABLE OF CONTENTS Chapter I – General Introduction 1 1. Steroids 3 1.1 Chemical structure 1.2 (Steroid) hormones and their role in the endocrine system 1.3 Biosynthesis of steroid hormones 1.4 Anabolic-androgenic steroids (AAS) 1.5 Synthesis and absorption of the steroid precursor cholesterol 2.
    [Show full text]
  • The Use of Capillary Electrophoresis (CE) in Drug Analysis
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 3-28-2005 The use of capillary electrophoresis (CE) in drug analysis Agnes D. Garcia Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Other Life Sciences Commons Recommended Citation Garcia, Agnes D., "The use of capillary electrophoresis (CE) in drug analysis" (2005). FIU Electronic Theses and Dissertations. 3928. https://digitalcommons.fiu.edu/etd/3928 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida THE USE OF CAPILLARY ELECTROPHORESIS (CE) IN DRUG ANALYSIS A thesis submitted in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE in FORENSIC SCIENCE by Agnes D. Garcia 2005 To: Dean R. Bruce Dunlap College of Arts and Sciences This thesis, written by Agnes D. Garcia, and entitled The Use of Capillary Electrophoresis (CE) in Drug Analysis, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this thesis and recommend that it be approved. Kenneth Furton Bruce McCord Jose R. Almirall, Major Professor Date of Defense: March 28,2005 The thesis of Agnes D. Garcia is approved. Dean R. Bruce Dunlap College of Arts and Sciences Dean Douglas Wartzok University Graduate School Florida International University, 2005 ii © Copyright 2005 by Agnes D.
    [Show full text]
  • UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST
    UFC PROHIBITED LIST Effective June 1, 2021 THE UFC PROHIBITED LIST UFC PROHIBITED LIST Effective June 1, 2021 PART 1. Except as provided otherwise in PART 2 below, the UFC Prohibited List shall incorporate the most current Prohibited List published by WADA, as well as any WADA Technical Documents establishing decision limits or reporting levels, and, unless otherwise modified by the UFC Prohibited List or the UFC Anti-Doping Policy, Prohibited Substances, Prohibited Methods, Specified or Non-Specified Substances and Specified or Non-Specified Methods shall be as identified as such on the WADA Prohibited List or WADA Technical Documents. PART 2. Notwithstanding the WADA Prohibited List and any otherwise applicable WADA Technical Documents, the following modifications shall be in full force and effect: 1. Decision Concentration Levels. Adverse Analytical Findings reported at a concentration below the following Decision Concentration Levels shall be managed by USADA as Atypical Findings. • Cannabinoids: natural or synthetic delta-9-tetrahydrocannabinol (THC) or Cannabimimetics (e.g., “Spice,” JWH-018, JWH-073, HU-210): any level • Clomiphene: 0.1 ng/mL1 • Dehydrochloromethyltestosterone (DHCMT) long-term metabolite (M3): 0.1 ng/mL • Selective Androgen Receptor Modulators (SARMs): 0.1 ng/mL2 • GW-1516 (GW-501516) metabolites: 0.1 ng/mL • Epitrenbolone (Trenbolone metabolite): 0.2 ng/mL 2. SARMs/GW-1516: Adverse Analytical Findings reported at a concentration at or above the applicable Decision Concentration Level but under 1 ng/mL shall be managed by USADA as Specified Substances. 3. Higenamine: Higenamine shall be a Prohibited Substance under the UFC Anti-Doping Policy only In-Competition (and not Out-of- Competition).
    [Show full text]
  • The Natural Compounds Atraric Acid and N-Butylbenzene-Sulfonamide
    The natural compounds atraric acid and N-butylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth Daniela Roell, Aria Baniahmad To cite this version: Daniela Roell, Aria Baniahmad. The natural compounds atraric acid and N-butylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth. Molec- ular and Cellular Endocrinology, Elsevier, 2010, 332 (1-2), pp.1. 10.1016/j.mce.2010.09.013. hal- 00654968 HAL Id: hal-00654968 https://hal.archives-ouvertes.fr/hal-00654968 Submitted on 24 Dec 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Accepted Manuscript Title: The natural compounds atraric acid and N-butylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth Authors: Daniela Roell, Aria Baniahmad PII: S0303-7207(10)00474-0 DOI: doi:10.1016/j.mce.2010.09.013 Reference: MCE 7644 To appear in: Molecular and Cellular Endocrinology Received date: 29-6-2010 Revised date: 3-9-2010 Accepted date: 27-9-2010 Please cite this article as: Roell, D., Baniahmad, A., The natural compounds atraric acid and N-butylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth, Molecular and Cellular Endocrinology (2010), doi:10.1016/j.mce.2010.09.013 This is a PDF file of an unedited manuscript that has been accepted for publication.
    [Show full text]
  • Effects of Zilpaterol and Melengestrol Acetate On
    EFFECTS OF ZILPATEROL AND MELENGESTROL ACETATE ON BOVINE SKELETAL MUSCLE GROWTH AND DEVELOPMENT by ERIN KATHRYN SISSOM B.S., California State University, Fresno, 2002 M.S., Kansas State University, 2004 AN ABSTRACT OF A DISSERTATION submitted in partial fulfillment of the requirements for the degree DOCTOR OF PHILOSOPHY Department of Animal Sciences and Industry College of Agriculture KANSAS STATE UNIVERSITY Manhattan, Kansas 2009 Abstract Zilpaterol (ZIL) is a β-adrenergic receptor (β-AR) agonist that has been recently approved for use in feedlot cattle to improve production efficiencies and animal performance. One of the mechanisms through which this occurs is increased skeletal muscle growth. Therefore, two experiments were conducted to determine the effects of ZIL both in vivo and in vitro . In the first experiment, ZIL addition to bovine satellite cells resulted in a tendency to increase IGF-I mRNA and increased myosin heavy chain IIA (MHC) mRNA with 0.001 µ M and decreased MHC mRNA with 0.01 and 10 µ M. There were no effects of ZIL on protein synthesis or degradation. In myoblast cultures, there was a decrease in all three β-AR mRNA, and this was also reported in western blot analysis with a reduction in β2-AR expression due to ZIL treatment. In myotubes, there was an increase in β2-AR protein expression. In the second and third experiment, ZIL improved performance and carcass characteristics of feedlot steers and heifers. Additionally, ZIL decreased MHC IIA mRNA in semimembranosus muscle tissue collected from both steers and heifers. An additional part of the third study was conducted to determine the effects of melengestrol acetate (MGA) on bovine satellite cell and semimembranosus muscle gene expression.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]